Why the study?
Does ondansetron ODT reduce postdischarge vomiting in ASA I and II patients undergoing outpatient gynecological laparoscopy?
Does ondansetron ODT reduce postdischarge vomiting in ASA I and II patients undergoing outpatient gynecological laparoscopy?
Ondansetron ODT significantly reduces the incidence of postdischarge nausea and vomiting and improves patient satisfaction after ambulatory surgery.
Answers are grounded in this paper and cite their sources.
Supports ondansetron ODT for postdischarge PONV prevention in outpatient gynecologic laparoscopy; extends RCT evidence to ambulatory discharge.
Ondansetron orally disintegrating tablet (ODT) is a new freeze-dried oral formulation of ondansetron. It does not require water to aid swallowing and is therefore easily administered to patients who have difficulty in swallowing or when nausea is making them reluctant to drink. It is absorbed via the gastrointestinal tract when the saliva is swallowed and its absorption kinetics are similar to the ondansetron tablet (1). There are no published data on the use of ondansetron ODT in preventing postdischarge nausea and vomiting (PDNV). The primary hypothesis of this study was that the administration of ondansetron ODT would result in a decreased incidence of postdischarge vomiting with a secondary hypothesis of a decreased incidence of nausea. Methods After IRB approval and written informed patient consent, 60 ASA I and II patients undergoing outpatient gynecological laparoscopy received a standardized general anesthetic incorporating fentanyl, propofol, and sevoflurane. All patients received a prophylactic dose of ondansetron 4 mg IV at induction. Immediately before discharge from the ambulatory surgery unit (ASU), patients were randomly allocated to receive ondansetron ODT 8 mg or identical placebo tablet and a second dose 12 h after. The incidence of postoperative nausea and vomiting (PONV), severity of nausea, rescue antiemetic, side effects profile, satisfaction with PONV management were assessed at 2 and 24 h (by telephone) after surgery by research personnel unaware of the randomization. Nausea was scored using an 11-point linear numerical scale from 0 to 10, with zero representing no nausea and 10 representing nausea “as bad as it can be.” The acceptability of the study drug (How did you rate the taste of the drug?) was assessed at 24 h using a similar scale where 0 represents “totally unacceptable” and 10 represents “extremely acceptable.” Patients were familiarized with the rating scales before surgery. Droperidol 1.25 mg IV was administered if a patient experienced two episodes of emesis in an hour or if it was requested by the patient. Satisfaction with management of PONV was assessed (2) and they were also asked if they would use the drug again. For estimation of sample size, the incidence of vomiting was used as a primary outcome. Pilot data revealed a baseline incidence of vomiting of 25%. Thirty patients per group was adequate to demonstrate a 60% reduction in the incidence of vomiting between two groups with α = 0.05 and β = 0.2. χ2 test, Wilcoxon’s Mann-Whitney U-test, and Fisher’s exact test were used where appropriate and a P value of <0.05 was considered statistically significant. Results Patients’ demographics were similar between groups. The incidence of pre- and PDNV, predischarge rescue antiemetic use, severity of nausea, patient satisfaction with PONV management, and acceptability of study drug are presented in Table 1. Ondansetron ODT patients had less severe nausea and fewer vomiting episodes after discharge from PACU compared with placebo patients. This group was also more satisfied with PONV control. However, the active drug was less acceptable to patients although they would use it again.Table 1: Patient Demographics, Incidence of Pre- and Postdischarge Nausea and Vomiting, Patient Satisfaction with PONV Management, and Acceptability of Ondansetron Orally Disintegrating TabletDiscussion PONV can and usually does persist beyond discharge from the ASU. Carroll et al. (3) demonstrated a 35% incidence of PDNV after ambulatory surgery. Most of these patients had not experienced the symptoms in the recovery room. Patients in the Placebo group in our study reported a more frequent incidence of postdischarge nausea (50%). This may be attributable to the frequent incidence of PONV in gynecological laparoscopy (4,5), as compared with a number of different surgical populations in Carroll et al.’s study (3), some of whom are associated with a decreased incidence of PONV. In another study, Gan et al. (6) demonstrated that PONV may persist up to 5 days after ambulatory surgery. The dosage of ondansetron ODT used is similar to that recommended for ondansetron oral tablet (8 mg). We chose to use this new formulation rather than the tablet formulation, as there are potential advantages of avoiding taking the drug with water and the costs were similar between the two formulations. It would be interesting to compare whether smaller doses were as effective, as have been demonstrated in a study using the IV formulation of ondansetron (7). Interestingly, patients rated the taste of ondansetron ODT less favorably than the placebo ODT. This may be because of the bitter aftertaste of the active ingredient. In summary, ondansetron ODT significantly reduces the incidence of PDNV, and improves patient satisfaction with PONV management after ambulatory surgery. However, additional comparative studies are needed to determine its role in clinical practice. The authors thank Habib El-Moalem, PhD, for statistical analysis.
No takes yet. Share an insight, caveat, or question.
Gan et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: